$BNTX

BioNTech shares fell 3% on Q1 revenue miss as COVID vaccine sales decline. Company announced €500M cost-cutting restructuring targeting 2029 completion.

Moderna beats revenue estimates with $389M vs. $227.97M consensus but shares fall 2.05% due to $2.22 per share litigation settlement charge.

Inventiva appoints three senior executives to strengthen leadership before Phase 3 lanifibranor data readout expected Q4 2026.

Over 100 pharmaceutical companies compete to develop 120+ NSCLC pipeline drugs, with 30+ in late-stage trials. Precision oncology advances drive innovation in biomarker-selected populations.

Anaveon appoints veteran biotech executive Thaminda Ramanayake as CEO to guide lead candidate ANV200 through clinical development for autoimmune and inflammatory diseases.

BioNTech shares plummeted as the biotech firm issued lower 2026 revenue guidance and co-founders announced plans to exit by year-end 2026.

Law firm investigates $BNTX following €305M Q4 loss, plunging COVID vaccine demand, and planned founder departure, examining potential securities law violations.

BioNTech shares plunge 14% as co-founders announce exit plan, with company cutting 2026 revenue guidance due to declining COVID demand.

Moderna settles $950M patent dispute with Arbutus and Genevant, clearing legal uncertainty. Stock surges 8.85% as company targets 2028 breakeven with $4.5-5B cash by 2026.

Large-cap stocks rallied on strong earnings and corporate actions. First Majestic Silver led with 25% gains, joined by Moderna and Global Payments on positive results.

BioNTech sues Moderna for patent infringement over next-gen COVID vaccine technology, claiming mNEXSPIKE violates its spike protein patents. Seeking damages for unlicensed use.